REGENERON PHARMACEUTICALS, INC. Accounts Receivable
REGENERON PHARMACEUTICALS, INC. (REGN) had Accounts Receivable of $6.57 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-07-30
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $6.57B.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $5.73B.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $5.74B.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $5.69B.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current | Accounts Receivable, after Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2026-06-30 | $6.57B 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $5.73B 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $5.74B 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $5.69B 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $5.61B 10-Q · filed 2025-08-01 | |
| 2025-03-31 | $5.56B 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $6.21B 10-K · filed 2026-02-04 | |
| 2024-09-30 | $6.11B 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $5.72B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $5.22B 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $5.67B 10-K · filed 2025-02-05 | |
| 2023-09-30 | $5.58B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $5.12B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $5.12B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $5.33B 10-K · filed 2024-02-05 | |
| 2022-09-30 | $5.55B 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $5.16B 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $4.84B 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $6.04B 10-K · filed 2023-02-06 | |
| 2021-09-30 | $5.45B 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $7.00B 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $4.17B 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $4.11B 10-K · filed 2022-02-07 | $3.11B 10-K · filed 2021-02-08 |
| 2020-09-30 | $3.09B 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $1.99B 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $2.06B 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $2.10B 10-K · filed 2021-02-08 | |
| 2019-09-30 | $2.03B 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $1.92B 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $1.73B 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $1.72B 10-K · filed 2020-02-07 | |
| 2018-09-30 | $1.67B 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $1.53B 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $1.53B 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $1.54B 10-K · filed 2019-02-07 | $1.54B 10-K · filed 2018-02-08 |
| 2017-09-30 | $1.53B 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $1.42B 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $1.34B 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $1.34B 10-K · filed 2018-02-08 | |
| 2016-09-30 | $1.33B 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $1.43B 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $1.45B 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $1.15B 10-K · filed 2017-02-09 | |
| 2015-09-30 | $1.09B 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $1.07B 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $1.02B 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $739.38M 10-K · filed 2016-02-11 | |
| 2014-09-30 | $673.91M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $664.08M 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $801.77M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $787.07M 10-K · filed 2015-02-12 | |
| 2013-09-30 | $855.84M 10-Q · filed 2013-11-05 | |
| 2013-06-30 | $767.87M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $703.86M 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $593.21M 10-K · filed 2014-02-13 | |
| 2012-09-30 | $506.68M 10-Q · filed 2012-10-24 | |
| 2012-06-30 | $349.64M 10-Q · filed 2012-07-25 | |
| 2012-03-31 | $159.46M 10-Q · filed 2012-04-26 | |
| 2011-12-31 | $28.25M 10-K · filed 2013-02-15 | |
| 2011-09-30 | $3.66M 10-Q · filed 2011-10-27 | |
| 2011-06-30 | $2.92M 10-Q · filed 2011-07-28 | |
| 2011-03-31 | $3.77M 10-Q · filed 2011-05-03 | |
| 2010-12-31 | $2.31M 10-K · filed 2012-02-21 | $13.51M 10-K · filed 2011-02-17 |
| 2010-09-30 | $3.05M 10-Q · filed 2010-10-28 | |
| 2010-06-30 | $4.07M 10-Q · filed 2010-07-28 | |
| 2009-12-31 | $2.87M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |